NutriBand (NTRB) Research & Development (2021 - 2026)
NutriBand (NTRB) posted Research & Development of $247261.0 for Q2 2026, up 31.5% sequentially from $188036.0 in Q1 2026, and down 63.82% YoY from $683426.0 in Q2 2025.
NutriBand (NTRB) Research & Development (2021 - 2026) Analysis & Trends
NutriBand has reported Research & Development for 6 years, with the latest figure at $247261.0 in Q2 2026.
- Quarterly Research & Development fell 63.82% year-over-year to $247261.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.5 million (down 48.55% YoY) and the FY2026 annual result came in at $1.9 million, down 39.37% from the prior year.
- Research & Development grew to $247261.0 in Q2 2026 per NTRB's latest filing, from $188036.0 in the prior quarter.
- Over five years, Research & Development peaked at $974535.0 in Q2 2024 and troughed at $117814.0 in Q2 2022.
- A 5-year average of $469475.5 and a median of $451117.5 in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2026: Research & Development jumped 239.88% in 2023, then slumped 63.82% in 2026.
- Over 5 years, Research & Development stood at $290718.0 in 2022, then soared by 89.7% to $551503.0 in 2023, then soared by 59.7% to $880768.0 in 2024, then sank by 48.1% to $457113.0 in 2025, then sank by 45.91% to $247261.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $247261.0, $188036.0, and $457113.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 97.90 Mn |
| 10 | NutriBand | 53.36 Mn | 49.36 Mn | 196,801.00 | 247,261.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 247,261.00 |
| Jan 31, 2026 | 188,036.00 |
| Oct 31, 2025 | 457,113.00 |
| Jul 31, 2025 | 562,554.00 |
| Apr 30, 2025 | 683,426.00 |
| Jan 31, 2025 | 489,856.00 |
| Oct 31, 2024 | 880,768.00 |
| Jul 31, 2024 | 773,975.00 |
| Apr 30, 2024 | 974,535.00 |
| Jan 31, 2024 | 563,370.00 |
| Oct 31, 2023 | 551,503.00 |
| Jul 31, 2023 | 445,122.00 |
| Apr 30, 2023 | 400,430.00 |
| Jan 31, 2023 | 295,826.00 |
| Oct 31, 2022 | 290,718.00 |
| Jul 31, 2022 | 277,869.00 |
| Apr 30, 2022 | 117,814.00 |
| Jan 31, 2022 | 250,383.00 |
| Oct 31, 2021 | 161,000.00 |